Morocco / Official Launch of the VigiMobile and VigiUp Platforms to Strengthen the National Health Surveillance System

The Moroccan Agency for Medicines and Health Products (AMMPS) officially launched VigiMobile and VigiUp on Wednesday in Rabat—two digital platforms designed to facilitate the reporting of adverse reactions related to medicines and health products.

Organized as part of the international drug safety awareness campaign "Med Safety Week 2026," which takes place from November 2 to 8 under the theme "Adverse events—don’t ignore them, report them,” this initiative is part of the effort to modernize the national health system, in accordance with the High Guidelines of His Majesty King Mohammed VI, aimed at ensuring health and drug safety.

The launch ceremony was attended by, among others, the Secretary General of the Ministry of Health and Social Protection, Abdelkrim Mezine Belfkih; the Director General of the AMMPS, Samir Ahid; institutional officials; representatives of healthcare facilities; and professionals in the sector.

Speaking at the event, the Minister of Health and Social Protection, Youns Bjijou, stated that with the launch of VigiMobile—for reporting adverse reactions related to medications and vaccines—and VigiUp—for other health products— “we are providing professionals and citizens with simple, readily accessible tools.”

In a speech read on his behalf by Mr. Meziane Belfkih, Mr. Bjijou emphasized the importance of health surveillance mechanisms in supporting health system reforms, as well as the need to promote a culture of reporting and to strengthen coordination among national and regional stakeholders.

The digital transformation of the national health system is not an end in itself, but it must simplify processes for users, improve the flow and processing of information, and strengthen institutions’ ability to identify and respond to risks, he noted, adding that these two platforms are a concrete example of this.

For his part, Mr. Ahid highlighted the Agency’s efforts to modernize surveillance systems, improve early risk detection, and facilitate the participation of healthcare professionals and citizens in ensuring the safety of medicines and health products, while reiterating the importance of strengthening the regional network for health surveillance through increased coordination among the various stakeholders in the healthcare system.

For the AMMPS, drug safety is not limited to marketing authorization but also relies on continuous monitoring, early risk detection, and a collective capacity to act to prevent any event that could compromise patient health, he said.

The meeting also featured a panel discussion on the theme: “Reporting: The Cornerstone of Vigilance—How Can We Make Every Healthcare Professional a Stakeholder in Patient Safety?”, highlighting the role of healthcare professionals in identifying and reporting adverse events and their contribution to risk prevention.

As part of MedSafety Week 2026, the AMMPS is also rolling out a nationwide and regional awareness program, including initiatives targeting university students to benefit future healthcare professionals, as well as community outreach activities conducted in coordination with the network of Regional Safety Monitoring Centers.

Source: www.mapexpress.ma/